nach oben

Erschienen in:

25.06.2018 | Neurological Update

The effect of fingolimod on focal and diffuse grey matter damage in active MS patients

verfasst von: Albulena Bajrami, Marco Pitteri, Marco Castellaro, Francesca Pizzini, Chiara Romualdi, Stefania Montemezzi, Salvatore Monaco, Massimiliano Calabrese

Erschienen in: Journal of Neurology | Ausgabe 9/2018

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The mechanism of action of fingolimod within the central nervous system and its efficacy in reducing/preventing both focal and diffuse grey matter (GM) damage in active multiple sclerosis (MS) are not completely understood.

Methods

In this longitudinal, 2-year prospective, phase IV, single-blind study, 40 MS patients treated with fingolimod and 39 untreated age, gender, and disability-matched MS patients were enrolled. Each patient underwent a neurological examination every 6 months and a 3T MRI at the beginning of the treatment and after 24 months. The accumulation of new cortical lesions (CLs) and the progression of regional GM atrophy were compared between the two groups.

Results

At the end of the study (T24), the percentage of patients with new CLs (13.5 vs. 89%, p < 0.001) and the percentage of GM volume change was lower in the treated group (p < 0.001). The regional analysis revealed that the treated group had also less volume loss in thalamus, caudatus, globus pallidus, cingulate cortex, and hippocampus (p < 0.001), as well as in, cerebellum, superior frontal gyrus, and insular-long gyrus (p < 0.05). Patients with no evidence of disease activity were 60% in the treated group and 10% in the untreated group (p < 0.001).

Conclusions

These results suggest a possible protective effect of fingolimod on focal and diffuse GM damage.

Noseworthy JH, Lucchinetti C, Rodriguez M et al (2000) Multiple sclerosis. N Engl J Med 343:938–952. https://doi.org/10.1056/NEJM200009283431307 CrossRefPubMed

Trapp BD, Peterson J, Ransohoff RM et al (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338:278–285. https://doi.org/10.1056/NEJM199801293380502 CrossRefPubMed

Peterson JW, Bö L, Mörk S et al (2001) Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 50:389–400CrossRefPubMed

Calabrese M, Romualdi C, Poretto V et al (2013) The changing clinical course of multiple sclerosis: a matter of gray matter. Ann Neurol 74:76–83. https://doi.org/10.1002/ana.23882 CrossRefPubMed

Calabrese M, Poretto V, Favaretto A et al (2012) Cortical lesion load associates with progression of disability in multiple sclerosis. Brain 135:2952–2961. https://doi.org/10.1093/brain/aws246 CrossRefPubMed

Calabrese M, Magliozzi R, Ciccarelli O et al (2015) Exploring the origins of grey matter damage in multiple sclerosis. Nat Rev Neurosci 16:147–158. https://doi.org/10.1038/nrn3900 CrossRefPubMed

Kappos L, Radue E-W, O’Connor P et al (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387–401. https://doi.org/10.1056/NEJMoa0909494 CrossRefPubMed

Cohen JA, Barkhof F, Comi G et al (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402–415. https://doi.org/10.1056/NEJMoa0907839 CrossRefPubMed

Oo ML, Thangada S, Wu M-T et al (2007) Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem 282:9082–9089. https://doi.org/10.1074/jbc.M610318200 CrossRefPubMed

10.

Pelletier D, Hafler DA (2012) Fingolimod for multiple sclerosis. N Engl J Med 366:339–347. https://doi.org/10.1056/NEJMct1101691 CrossRefPubMed

11.

Pitteri M, Magliozzi R, Bajrami A et al (2018) Potential neuroprotective effect of Fingolimod in multiple sclerosis and its association with clinical variables. Expert Opin Pharmacother 19:387–395. https://doi.org/10.1080/14656566.2018.1434143 CrossRefPubMed

12.

Foster CA, Howard LM, Schweitzer A et al (2007) Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther 323:469–475. https://doi.org/10.1124/jpet.107.127183 CrossRefPubMed

13.

Mullershausen F, Zecri F, Cetin C et al (2009) Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. Nat Chem Biol 5:428–434. https://doi.org/10.1038/nchembio.173 CrossRefPubMed

14.

Colombo E, Di Dario M, Capitolo E et al (2014) Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide. Ann Neurol 76:325–337. https://doi.org/10.1002/ana.24217 CrossRefPubMed

15.

Hoffmann FS, Hofereiter J, Rübsamen H et al (2015) Fingolimod induces neuroprotective factors in human astrocytes. J Neuroinflamm 12:184. https://doi.org/10.1186/s12974-015-0393-6 CrossRef

16.

Cui QL, Fang J, Kennedy TE et al (2014) Role of p38MAPK in S1P receptor-mediated differentiation of human oligodendrocyte progenitors. Glia 62:1361–1375. https://doi.org/10.1002/glia.22688 CrossRefPubMed

17.

Cipriani R, Chara JC, Rodríguez-Antigüedad A et al (2017) Effects of FTY720 on brain neurogenic niches in vitro and after kainic acid-induced injury. J Neuroinflamm 14:147. https://doi.org/10.1186/s12974-017-0922-6 CrossRef

18.

Landi D, Vollaro S, Pellegrino G et al (2015) Oral fingolimod reduces glutamate-mediated intracortical excitability in relapsing–remitting multiple sclerosis. Clin Neurophysiol 126:165–169. https://doi.org/10.1016/j.clinph.2014.05.031 CrossRefPubMed

19.

Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1452CrossRefPubMed

20.

Geurts JJG, Roosendaal SD, Calabrese M et al (2011) Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI. Neurology 76:418–424. https://doi.org/10.1212/WNL.0b013e31820a0cc4 CrossRefPubMed

21.

Geurts JJG, Bö L, Pouwels PJW et al (2005) Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. AJNR Am J Neuroradiol 26:572–577PubMedPubMedCentral

22.

Seewann A, Vrenken H, Kooi E-J et al (2011) Imaging the tip of the iceberg: visualization of cortical lesions in multiple sclerosis. Mult Scler J 17:1202–1210. https://doi.org/10.1177/1352458511406575 CrossRef

23.

Seewann A, Kooi E-J, Roosendaal SD et al (2012) Postmortem verification of MS cortical lesion detection with 3D DIR. Neurology 78:302–308. https://doi.org/10.1212/WNL.0b013e31824528a0 CrossRefPubMed

24.

Sethi V, Yousry T, Muhlert N et al (2016) A longitudinal study of cortical grey matter lesion subtypes in relapse-onset multiple sclerosis. J Neurol Neurosurg Psychiatry 87:750–753. https://doi.org/10.1136/jnnp-2015-311102 CrossRefPubMed

25.

Havrdova E, Galetta S, Stefoski D et al (2010) Freedom from disease activity in multiple sclerosis. Neurology 74(Suppl 3):S3–S7. https://doi.org/10.1212/WNL.0b013e3181dbb51c CrossRefPubMed

26.

Giovannoni G, Turner B, Gnanapavan S, Offiah C, Schmierer K, Marta M (2015) Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord 4(4):329–333. https://doi.org/10.1016/j.msard.2015.04.006 CrossRefPubMed

27.

Gaetano L, Häring DA, Radue E-W et al (2018) Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis. Neurology 90:e1324–e1332. https://doi.org/10.1212/WNL.0000000000005292 CrossRefPubMed

28.

Calabrese M, Bernardi V, Atzori M et al (2012) Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing–remitting multiple sclerosis. Mult Scler J 18:418–424. https://doi.org/10.1177/1352458510394702 CrossRef

29.

Barkhof F, de Jong R, Sfikas N et al (2014) The influence of patient demographics, disease characteristics and treatment on brain volume loss in trial assessing injectable interferon vs FTY720 oral in relapsing–remitting multiple sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Mult Scler 20:1704–1713. https://doi.org/10.1177/1352458514532317 CrossRefPubMed

30.

Calabresi P, Radue E-W, Goodin D et al (2014) Safety and efficacy of fingolimod in patients with relapsing–remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 13:545–556. https://doi.org/10.1016/S1474-4422(14)70049-3 CrossRefPubMed

31.

Claes N, Dhaeze T, Fraussen J et al (2014) Compositional changes of B and T CELL subtypes during fingolimod treatment in multiple sclerosis patients: a 12-month follow-up study. PLoS One 9:e111115. https://doi.org/10.1371/journal.pone.0111115 CrossRefPubMedPubMedCentral

32.

Brinkmann V, Billich A, Baumruker T et al (2010) Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 9:883–897. https://doi.org/10.1038/nrd3248 CrossRefPubMed

33.

Lucchinetti CF, Popescu BFG, Bunyan RF et al (2011) Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 365:2188–2197. https://doi.org/10.1056/NEJMoa1100648 CrossRefPubMedPubMedCentral

34.

De Stefano N, Matthews PM, Filippi M et al (2003) Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology 60:1157–1162CrossRefPubMed

35.

Ceccarelli A, Rocca MA, Pagani E et al (2008) A voxel-based morphometry study of grey matter loss in MS patients with different clinical phenotypes. Neuroimage 42:315–322. https://doi.org/10.1016/j.neuroimage.2008.04.173 CrossRefPubMed

36.

Audoin B, Zaaraoui W, Reuter F et al (2010) Atrophy mainly affects the limbic system and the deep grey matter at the first stage of multiple sclerosis. J Neurol Neurosurg Psychiatry 81:690–695. https://doi.org/10.1136/jnnp.2009.188748 CrossRefPubMed

37.

Geurts JJG, Bö L, Roosendaal SD et al (2007) Extensive hippocampal demyelination in multiple sclerosis. J Neuropathol Exp Neurol 66:819–827. https://doi.org/10.1097/nen.0b013e3181461f54 CrossRefPubMed

38.

Calabrese M, Castellaro M, Bertoldo A et al (2017) Epilepsy in multiple sclerosis: the role of temporal lobe damage. Mult Scler J 23:473–482. https://doi.org/10.1177/1352458516651502 CrossRef

39.

Giovannoni G, Tomic D, Bright JR, Havrdová E (2017) “No evident disease activity”: the use of combined assessments in the management of patients with multiple sclerosis. Mult Scler 23(9):1179–1187. https://doi.org/10.1177/1352458517703193 CrossRefPubMedPubMedCentral

Titel: The effect of fingolimod on focal and diffuse grey matter damage in active MS patients
verfasst von: Albulena Bajrami
Marco Pitteri
Marco Castellaro
Francesca Pizzini
Chiara Romualdi
Stefania Montemezzi
Salvatore Monaco
Massimiliano Calabrese
Publikationsdatum: 25.06.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Neurology / Ausgabe 9/2018
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-018-8952-2

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

18.04.2024 | Arterielle Hypertonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

The effect of fingolimod on focal and diffuse grey matter damage in active MS patients

Abstract

Introduction

Methods

Results

Conclusions

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Manche Gestagene können das Risiko für Meningeome erhöhen

Parkinson: Größere Studie bestätigt Genauigkeit von Hauttest

Update Neurologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Introduction

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2018

Validation of a novel Montreal Cognitive Assessment scoring algorithm in non-demented Parkinson’s disease patients

Sneddon syndrome and non-bacterial thrombotic endocarditis: a clinicopathological study

Corpus callosal involvement is correlated with cognitive impairment in multiple system atrophy

Coordination and timing deficits in speech and swallowing in autosomal recessive spastic ataxia of Charlevoix–Saguenay (ARSACS)

Coexisting narcolepsy (with and without cataplexy) and multiple sclerosis

The discriminative value of blood gas analysis parameters in the differential diagnosis of transient disorders of consciousness

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Manche Gestagene können das Risiko für Meningeome erhöhen

Parkinson: Größere Studie bestätigt Genauigkeit von Hauttest

Update Neurologie